Would you consider using a PARP inhibitor in a patient with metastatic pancreatic cancer with a germline ATM mutation after progression on FOLFIRINOX and gemcitabine based chemotherapy?
Answer from: Medical Oncologist at Community Practice
I would not use a PARP inhibitor in this situation. The available evidence on PARP inhibitors in pancreatic cancer is in the first-line maintenance setting, among patients with germline BRCA mutations (and now also among patients with somatic BRCA mutations and with germline PALB2 mutations). So cur...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I would not. In addition to the nice explanation above, MSKCC led a small trial in a similar population with dismal response to PARPi. Lowery et al., PMID 29223478 12 out of 16 patients had PD as their best documented response. PFS was 1.7 months.